COMMUNIQUÉS West-GlobeNewswire

Sienna Announces December Dividend
15/12/2025
MARKHAM, Ontario, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) [...]
OKYO Pharma Announces Chairman and Founder Acquires Shares
15/12/2025
LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an [...]
TOMI Environmental Solutions Calls Upon Cruise Lines to Improve Decontamination and Adopt Hospital-Grade Technology Like SteraMist to Safeguard Passengers and Crew
15/12/2025
FREDERICK, Md., Dec. 15, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, is calling upon cruise lines to improve [...]
HeartSciences Announces FDA 510(k) Submission for MyoVista® wavECG™ Device
15/12/2025
Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing the use of ECG/EKGs through the [...]
ORYZON Announces the Voting Results of December 2025 Extraordinary General Shareholders' Meeting
15/12/2025
37.8% of voting rights present or represented All resolutions were approved MADRID and CAMBRIDGE, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage [...]
Noom Enters Longevity Health Space with Proactive Health Microdose GLP-1Rx Program Designed to Help Millions Address the Biomarkers Most Linked to Future Disease
15/12/2025
New program pairs microdoses of GLP-1 medication with Noom’s powerful behavior-change program and at-home biomarker testing to track the health impact of combining GLP-1 therapy with healthy habits. PRINCETON, N.J., Dec [...]
Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
15/12/2025
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest that nuclear GSK-3β expression may help identify patients most likely to respond to treatment of a [...]
SPR Reaches Milestone 50,000th Implant of the SPR® SPRINT® PNS System
15/12/2025
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- SPR announced that it has reached 50,000 implants of the SPRINT ® PNS System, a significant milestone recognizing the impact of treatment for patients with 60-day peripheral [...]
BetaGlue Therapeutics obtient l’autorisation du ministère de la Santé belge pour mener un essai clinique portant sur YntraDose dans le traitement du cancer du pancréas localement avancé non résécable (uLA-PDAC)
15/12/2025
MILAN, 15 déc. 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (« BetaGlue » ou la « Société »), une société italienne pionnière en oncologie au stade clinique, développant une solution innovante de radiothérapie pour [...]
BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
15/12/2025
MILAN, Dec. 15, 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (“BetaGlue” or the “Company”), a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted [...]
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01
15/12/2025
STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
15/12/2025
15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, [...]
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire du tolébrutinib dans la sclérose en plaques secondaire progressive non-récurrente
15/12/2025
Sanofi fait le point sur la soumission réglementaire du tolébrutinib dans la sclérose en plaques secondaire progressive non-récurrente Les discussions en cours avec la FDA concernant la demande pour la SEPSPnr indiquent [...]
Press Release : Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis
15/12/2025
Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Ongoing discussions with the FDA regarding nrSPMS application have indicated regulatory decision for [...]
La protonthérapie, nouvelle norme de soins pour les patients atteints d'un cancer de l'oropharynx
15/12/2025
Louvain-la-Neuve, Belgique, le 15 décembre 2025 - IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d’accélération de particules et principal fournisseur de solutions de protonthérapie pour [...]
Proton Therapy New Standard of Care for Patients with Oropharyngeal Cancer
15/12/2025
Louvain-La-Neuve, Belgium, December 15, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the [...]
Communiqué de presse : Sanofi fait le point sur le tolébrutinib dans la sclérose en plaques primaire progressive
15/12/2025
Sanofi fait le point sur le tolébrutinib dans la sclérose en plaques primaire progressive L'étude de phase 3 PERSEUS dans la sclérose en plaques primaire progressive n'a pas atteint son critère d'évaluation principal de [...]
Press Release: Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis
15/12/2025
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month [...]
Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI
15/12/2025
December 15, 2025 Acquisition of SpectraWAVE’s next-generation technologies including HyperVue TM Imaging System with Enhanced Vascular Imaging for comprehensive, rapid, and AI-supported imaging inside the coronary [...]

Pages